Exagen  logo
Exagen XGN
$ 3.13 2.29%

Annual report 2025
added 03-10-2026

report update icon

Exagen Income Statement 2011-2026 | XGN

Annual Income Statement Exagen

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

70.1 M 59.2 M 31.3 M 40.3 M 121 M 199 M 80.5 M - - - - - - - -

Shares

21.6 M 18.2 M 17.7 M 17.1 M 16 M 12.7 M 3.58 M - - - - - - - -

Historical Prices

3.25 3.25 1.77 2.36 7.6 18.3 17.1 - - - - - - - -

Net Income

-20 M -15.1 M -23.7 M -47.4 M -26.9 M -16.7 M -12 M -8.01 M -25.6 M - -19.2 M -15 M -13.5 M -7.32 M -

Revenue

66.6 M 55.6 M 52.5 M 45.6 M 48.3 M 42 M 40.4 M 32.4 M 26.8 M - 17.9 M 11.7 M 3.06 M 926 K -

Cost of Revenue

27.8 M 22.5 M 23.1 M 24.2 M 20.6 M 16.6 M 18.8 M 15.4 M - - - - - - -

Gross Profit

38.8 M 33.1 M - - - 25.4 M 21.6 M 17.1 M 12.7 M - 8.41 M 4.78 M 225 K -1.05 M -

Operating Income

-14.1 M -13.6 M -22.8 M -46.1 M -24.1 M -15.2 M -9.3 M -4.88 M - - - - - - -

Interest Expense

- - 2.34 M 2.45 M 2.62 M 2.56 M 3.49 M 2.87 M - - - - - - -

EBITDA

-12 M -11.9 M -20.6 M -44.5 M -23.2 M -14.6 M -8.71 M -4.74 M -7.7 M - -10.4 M -11.6 M -7.66 M -7.25 M -

Operating Expenses

- - - - - 40.6 M 30.9 M 21.9 M 20.6 M - 19.1 M 16.6 M 8.1 M 6.42 M -

General and Administrative Expenses

46.6 M 41.4 M 47.4 M 52 M 44.5 M 37 M 28.7 M - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Exagen

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

22.9 M 21.1 M 18.6 M 17.6 M 18.3 M 18.2 M 17.9 M 17 M 17.7 M 17.7 M 17.5 M 16.5 M 17.1 M 17.1 M 17 M 16.2 M 16.9 M 16.9 M 12.9 M 12.7 M 12.6 M 12.6 M 12.6 M 12.6 M 1.51 M 63 K 63 K 63 K 63 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-7.09 M -4.44 M -3.75 M - -5.03 M -2.97 M -3.36 M - -5.42 M -5.01 M -7.69 M - -8.1 M -14.7 M -10.3 M - -7.18 M -6.41 M -6.21 M - -4.31 M -3.36 M -5.56 M - -3.14 M -2.78 M -2.7 M - -1.76 M -2.15 M -2.79 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

17.2 M 17.2 M 15.5 M - 12.5 M 15.1 M 14.4 M - 13.4 M 14.1 M 11.2 M - 14.7 M 7.61 M 10.4 M - 12.3 M 12.8 M 10.6 M - - 8.95 M 9.58 M - 10.4 M 10.5 M 9.26 M - 8.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

7.17 M 6.81 M 6.38 M - 5.53 M 6.01 M 5.82 M - 5.71 M 5.84 M 5.93 M - 6.01 M 6.08 M 5.82 M - 5.49 M 5.45 M 4.71 M - 4.34 M 3.34 M 4.54 M - 400 K 4.99 M 4.44 M - 3.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

10.1 M 10.4 M 9.12 M - 6.98 M 9.06 M 8.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-3.1 M -2.63 M -3.36 M - -4.66 M -2.59 M -3 M - -5.07 M -4.92 M -7.71 M - -7.82 M -14.1 M -9.68 M - -6.5 M -5.74 M -5.57 M - -3.79 M -3.42 M -5.22 M - -2.16 M -2.41 M -1.87 M - -1.13 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - 549 K - 557 K 574 K 638 K - 618 K 606 K 598 K - 678 K 663 K 645 K - 647 K 635 K 631 K - 909 K 910 K 901 K - 704 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-2.5 M -2.13 M -2.96 M - -4.26 M -2.19 M -2.5 M - -4.47 M -4.42 M -7.11 M - -7.42 M -13.8 M -9.38 M - -6.2 M -5.54 M -5.37 M - -3.69 M -3.22 M -5.12 M - -2.06 M -2.21 M -1.67 M - -933 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

11.4 M 11.5 M 11.2 M - 10.2 M 10.5 M 10.5 M - 11.4 M 12 M 11.9 M - 14.2 M 12.9 M 12.2 M - 11.5 M 11.2 M 10 M - 9.2 M 8.28 M 9.63 M - 7.31 M 7.3 M 6.18 M - 4.93 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Exagen (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 114.25 -1.07 % $ 34.7 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.64 3.53 % $ 85.7 K usaUSA
Biodesix Biodesix
BDSX
$ 15.55 3.19 % $ 2.02 B usaUSA
Biomerica Biomerica
BMRA
$ 2.17 - $ 4.98 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.2 -0.03 % $ 6.53 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.5 1.85 % $ 178 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 18.32 0.05 % $ 976 M usaUSA
Celcuity Celcuity
CELC
$ 113.8 1.04 % $ 5.32 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 5.85 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 168.44 -3.13 % $ 8.35 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 24.85 0.04 % $ 690 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 197.89 0.37 % $ 22 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 190.62 -0.26 % $ 136 B usaUSA
DexCom DexCom
DXCM
$ 62.7 0.76 % $ 24.5 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Fulgent Genetics Fulgent Genetics
FLGT
$ 16.8 -0.15 % $ 508 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Guardant Health Guardant Health
GH
$ 92.35 -1.58 % $ 11.6 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 110.38 -3.34 % $ 9.1 B irlandaIrlanda
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.96 5.82 % $ 8.67 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Illumina Illumina
ILMN
$ 127.63 0.2 % $ 20.3 B usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 168.24 -2.9 % $ 28.9 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 274.94 0.41 % $ 22.9 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 76.0 -0.14 % $ 5.13 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 485.89 -2.5 % $ 14 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 258.2 -0.3 % $ 25.9 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 4.84 1.79 % $ 448 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.69 - $ 3.69 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.06 0.75 % $ 1.03 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.42 0.11 % $ 2.04 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.35 1.11 % $ 388 M usaUSA
Natera Natera
NTRA
$ 207.01 -0.46 % $ 20.4 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.36 1.49 % $ 408 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 27.09 -0.07 % $ 20 B niderlandNiderland
Precipio Precipio
PRPO
$ 25.23 -1.29 % $ 40.5 M usaUSA
Personalis Personalis
PSNL
$ 6.63 0.76 % $ 393 M usaUSA
RadNet RadNet
RDNT
$ 55.12 0.6 % $ 4.14 B usaUSA